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Abstract
A novel parvovirus was discovered recently in the brain of a harbor seal (Phoca vitulina) with chronic meningo-encephalitis.
Phylogenetic analysis of this virus indicated that it belongs to the genus Erythroparvovirus, to which also human parvovirus
B19 belongs. In the present study, the prevalence, genetic diversity and clinical relevance of seal parvovirus (SePV) infections
was evaluated in both harbor and grey seals (Halichoerus grypus) that lived in Northwestern European coastal waters from
1988 to 2014. To this end, serum and tissue samples collected from seals were tested for the presence of seal parvovirus
DNA by real-time PCR and the sequences of the partial NS gene and the complete VP2 gene of positive samples were
determined. Seal parvovirus DNA was detected in nine (8%) of the spleen tissues tested and in one (0.5%) of the serum
samples tested, including samples collected from seals that died in 1988. Sequence analysis of the partial NS and complete
VP2 genes of nine SePV revealed multiple sites with nucleotide substitutions but only one amino acid change in the VP2
gene. Estimated nucleotide substitution rates per year were 2.0061024 for the partial NS gene and 1.1561024 for the
complete VP2 gene. Most samples containing SePV DNA were co-infected with phocine herpesvirus 1 or PDV, so no
conclusions could be drawn about the clinical impact of SePV infection alone. The present study is one of the few in which
the mutation rates of parvoviruses were evaluated over a period of more than 20 years, especially in a wildlife population,
providing additional insights into the genetic diversity of parvoviruses.
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Introduction
Parvoviruses are small, non-enveloped, viruses with linear,
single-stranded DNA genomes of approximately 5 kb. The family
Parvoviridae comprises two subfamilies: Parvovirinae and
Densovirinae. Members of the Parvovirinae infect vertebrates,
while members of the Densovirinae infect invertebrates [1]. At
present, eight genera have been recognized by the International
Committee on Taxonomy of Viruses (ICTV) within the subfamily
Parvovirinae: Amdoparvovirus, Aveparvovirus, Bocaparvovirus,
Copiparvovirus, Dependoparvovirus, Erythroparvovirus, Proto-
parvovirus and Tetraparvovirus [2,3].
The genus Erythroparvovirus currently consists of six species,
Primate erythroparvoviruses 1–4, Rodent erythroparvovirus 1 and
Ungulate erythroparvovirus 1 [2,3]. Human parvovirus B19 or
Primate erythroparvovirus 1 is the best studied member of this
genus. It is prevalent worldwide; more than 15% of pre-school
children, 50% of younger adults and 85% of the elderly have
serologic evidence of infection based on data from Australia,
Denmark, England, Japan, and the USA [4]. Infection by human
parvovirus B19 can be asymptomatic or symptomatic, with clinical
manifestations ranging from mild erythema infectiosum (fifth
disease) in healthy children to chronic arthropathy in adults,
transient aplastic crisis in patients with underlying hematologic
disease, and hydrops fetalis [4–6]. In addition, involvement of
human parvovirus B19 in encephalitis and other neurologic
diseases was suggested by serology and viral DNA detection by
PCR of the cerebrospinal fluid of patients [7]. Other members of
the genus Erythroparvovirus; simian parvovirus, rhesus macaque
parvovirus, and pig-tailed macaque parvovirus (Primate erythro-
parvoviruses 2, 3, 4), are associated with anemia in the respective
non-human primates [8,9]. Chipmunk parvovirus (Rodent ery-
throparvovirus 1) and bovine parvovirus type 3 (Ungulate
erythroparvovirus 1) are also members of this genus and were
identified in apparently healthy animals [10,11].
Recently, a novel parvovirus, tentatively called seal parvovirus
(SePV), was identified in the brain and lungs tissues of a young
harbor seal (Phoca vitulina) with severe chronic neurological signs
[12]. Phylogenetic analysis suggested that this virus belonged to
the genus Erythroparvovirus. Histological examination of the
brain of the infected seal confirmed the presence of a chronic non-
suppurative meningo-encephalitis, while other causes of brain
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disease, such as neoplasia, physical trauma, and infections with
herpesvirus or morbillivirus, were excluded. In situ hybridization
showed that the novel SePV DNA was present in the Virchow-
Robin spaces and in the brain parenchyma adjacent to the
meninges of the seal [12]. This discovery showed that parvoviruses
indeed can enter the brain parenchyma.
During a previous study using tissue samples collected from
necropsies in 2008–2012, SePV DNA was detected in only two out
of 94 additional seals [12]. In the present study, this prevalence
study was extended using tissues and sera collected from both
harbor and grey seals (Halichoerus grypus) from Northwestern
European coastal waters from 1988 to 2014. In addition, we
investigated the genetic diversity, estimated nucleotide substitution
rates and evaluated the clinical relevance of SePV infections.
Materials and Methods
Ethics statement
Samples of seals used in the present study were provided by the
Seal Research and Rehabilitation Centre (SRRC), and the SRRC
provided permission to the Department of Viroscience, Erasmus
Medical Centre to use the samples for the present study.
Admission and rehabilitation of wild seals at the SRRC is
permitted by the government of the Netherlands (application
number FF/75/2012/015). In the present study, only samples
were used that were collected from dead seals or blood samples
that were collected for routine diagnostics during rehabilitation.
These samples were collected from seals that were either found
dead in the wild by the SRRC, died at the SRRC despite intensive
care or were euthanized at the SRRC due to the presence of
severe clinical signs in the absence of any indication of future
recovery. In case of euthanasia, this was performed with T-61
(0.3 ml/kg) after sedation as described previously [13]. Tissue
samples that were used in the present study have been described
previously [12,14–17].
Sample collection
Blood samples were collected from harbor (n = 131) and grey
seals (n = 69) of different age groups rehabilitated from 2002–2014
at the SRRC, Pieterburen, the Netherlands and after clotting,
samples were centrifuged briefly and serum was stored at 220uC
until further processing. Samples of spleen tissue (n = 110) were
collected from both harbor seals (n = 99) and grey seals (n = 11)
that died during outbreaks of phocine distemper virus (PDV)
among seals of Northwestern Europe in 1988 and 2002 [16,18]
and in-between years (1988–2002) and stored at 280uC until
further processing. An overview of samples used in the present
study is listed in Table S1. Seals were defined into three different
age categories; pups (estimated to be less than two months of age),
juveniles (estimated to be between two and twelve months of age)
and (sub)adults (estimated to be older than one year of age).
SePV DNA detection
In previous studies of humans infected with parvovirus B19,
viral DNA could not be detected in blood samples, but was
detected in tissues such as bone marrow, tonsils, synovium, and
lymphoid tissues [19,20]. Since replication of SePV was observed
in vitro in seal bone marrow cells, this might be also applicable for
SePV [12]. However, since bone marrow samples were not
available, spleen tissue samples were selected. These samples were
homogenized in 1 ml Hank’s minimal essential medium (HMEM)
containing 0.5% lactalbumin, 10% glycerol, 200 U/ml penicillin,
200 mg/ml streptomycin, 100 U/ml polymyxin B sulfate, 250 mg/
ml gentamycin, and 50 U/ml nystatin (ICN Pharmaceuticals)
(transport medium) using a Fastprep-24 Tissue Homogenizer (MP
Biomedicals) and centrifuged briefly. Total nucleic acids were
extracted from serum (50 ml) and homogenized spleen tissue
(200 ml) using the High Pure Viral Nucleic Acid kit (Roche)
according to the instructions of the manufacturer. Samples were
screened for SePV DNA using a real-time PCR targeting the VP1
gene as described previously [12]. Each sample was tested at least
in two independent experiments and to avoid false positive
samples due to cross-contamination during mass necropsies, only
samples that yielded a cycle threshold (Ct) value below 35 were
considered positive.
Sequencing of the partial genome of SePV variants
On samples that tested positive by real-time PCR, additional
specific PCRs were performed to amplify the partial NS (924 bp)
and the complete VP2 gene. The partial NS gene was amplified
with forward primer TAGAATGGCTTGTGCGGTGT and
reverse primer GTGGGTTTCAATGGCCTACT. The complete
VP2 gene was amplified using two partial overlapping primer sets,
with forward primer TTGCCGGCCATCTCGTCGTA and
reverse primer AGCCTGTCCTTCATCTGACC targeting the
59end of the gene and forward primer TCTCAGGCT-
CAATGGCGTAG and reverse primer GTGAAGCTT-
TATTTTTGGGCAC targeting the 39 end of the gene. PCR
products were separated by gel electrophoresis, bands of the
appropriate size were extracted using the MinElute Gel Extraction
Kit (Qiagen) and cloned using the TOPO TA Cloning Kit for
Sequencing (Invitrogen). Multiple clones were sequenced with an
ABI Prism 3130xl genetic analyzer (Applied Biosystems). For
sequence analysis, a consensus sequence was deduced from at least
three colonies for each sample.
Phylogenetic analysis, estimation of substitution rates
and selection pressure
Obtained nucleotide sequences of the complete VP2 and partial
NS genes of SePV variants were aligned with various other viruses
belonging to the genus Erythroparvovirus using MAFFT7 [21].
Subsequently, a maximum likelihood phylogenetic tree was built
in MEGA6 [22] with 500 bootstrap values using the Jukes Cantor
model, which was selected by analysis with jModeltest 2.1.3 [23].
The number of nucleotide substitutions per site per year was
estimated with a Bayesian Markov Chain Monte Carlo (MCMC)
method implemented in the BEAST 1.7 package [24]. Dates of
sequences were used in combination with the HKY substitution
model and a log-normal relaxed clock. The analysis was
conducted using a time-aware linear Bayesian skyride coalescent
tree prior [25]. Three independent MCMC analyses were
performed for 10 million states. These analyses were combined
and analyzed with Tracer, version 1.5. Uncertainty in parameter
estimates was reported as the 95% highest posterior density
(HPD). The selective pressures on the NS and VP2 genes were
assessed by calculating the ratio between non-synonymous
substitutions (dN) and synonymous substitutions (dS) per site using
the single likelihood ancestor counting (SLAC) method imple-
mented in HyPhy platform accessed via the DataMonkey web-
server (www.datamonkey.org) [26].
Analysis of the clinical relevance of SePV infection
The clinical or pathological reports of seals that tested positive
for SePV DNA were retrospectively analyzed. Available informa-
tion included age group (pups ,2 months of age, juveniles .2
months and ,1 year of age, (sub)adults .1 year of age), sex, gross
pathology results and possible cause of death (only for tissue
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samples), and hematology results (only for the serum samples).
Since in a previous study co-infection with herpesvirus was
detected in most cases, samples positive for SePV DNA were tested
for the presence of co-infection with herpesvirus using a
degenerate nested pan-herpesvirus PCR targeting the conserved
DNA polymerase gene, as described previously [27]. PCR
products with the appropriate band size were sequenced and
obtained sequences were analyzed by BLAST search to determine
which herpesvirus was detected.
Results
Prevalence of SePV infection
Out of 200 seal serum samples from 2002–2014 analyzed, only
one sample had a Ct-value ,35 (0.5%), which was the serum of a
grey seal from 2006 (rehabilitation number: HG 06-130). In
addition, in 9 out of 110 spleen tissue samples, the Ct-value was
lower than 35 (8%). Of those nine samples, two were collected
from harbor seals that had died during the 1988 and seven during
the 2002 PDV outbreaks (six harbor seals and one grey seal).
Combination of the data obtained in the present study with data
from a previous study [12], resulted in a SePV prevalence in
spleen samples of 6.9% for harbor seals (based on in total 174
animals) and 9.1% for grey seals (n = 11) (Figure S1, Table 1).
Genetic analysis of SePV
Out of 12 samples in which SePV DNA was detected by real-
time PCR (including samples from a previous study [12]), the
partial NS (Genbank accession numbers: KM252699-KM252706)
and the complete VP2 gene (Genbank accession numbers
KM252691-KM252698) could be amplified in only 9 samples,
possibly due to fragmentation of the DNA or inhibiting factors
present in the other samples. Analysis of the obtained nucleotide
sequences showed that SePV from 1988 to 2012 displayed
minimal sequence variation. Using the parvovirus detected in
the oldest sample (SePV-PV880823.6) as a reference, 12 (1.3%)
variant nucleotide positions were present in the partial NS gene
(Figure 1), of which ten were transitions and two were
transversions, and all 12 were synonymous. At three nucleotide
positions (positions 957, 1098, and 1446) mutations were fixed in
the viruses detected after 1988. All the nucleotide substitutions
occurred in the third codon base. Compared to the viruses
detected in 1988, the virus with the highest number of nucleotide
substitutions was SePV-PV121216.01, which was detected in 2012
(Figure 1). Estimated nucleotide substitution rates of the partial
NS were 2.0061024 (HPD, 1.3661025–4.0461024) nucleotide
substitutions per site per year.
In the complete VP2 gene, 13 (0.76%) variant nucleotide
positions were present, including 11 transitions and 2 transver-
sions. Among those, 11 occurred in the third codon base and 2 in
the first codon base. In the SePV detected in a harbor seal
Figure 1. Variation in SePV sequences. Schematic overview of the partial NS gene and the complete VP2 gene that was amplified of 9 SePV
variants. The consensus sequence of each virus was compared to the oldest sample available (HSePV-PV880823.6). Locations with nucleotide
mutations are indicated in grey. Only in sample HSePV-121216.01, a nucleotide mutation resulted in an amino acid substitution (S540T).
doi:10.1371/journal.pone.0112129.g001
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(identification number PV121216.01), a mutation at nucleotide
position 4792 was present, which resulted in an amino acid change
from serine to threonine (amino acid residue 540). For the VP
gene, we found nucleotide substitution rates of 1.1561024 (HPD,
1.4361025–2.2261024) nucleotide substitutions per site per year
with a dN/dS value of 0.33.
The high similarity of different SePV variants was reflected by
phylogenetic and pairwise identity analysis of the NS and VP2
nucleotide sequences. Pairwise identities between SePV NS
variants were 99.3% or higher and between SePV VP2 variants
99.5% or higher, while pairwise identities between SePV and
other parvoviruses belonging to the genus Erythroparvovirus were
51.9% or lower for the NS gene and 50.6% or lower for the VP2
gene (Figure 2).
Evaluation of the clinical relevance of SePV infection
Available clinical and pathology data of the seals from which
positive samples were obtained, including two positive seals
detected in a previous study [12], showed that SePV DNA was
detected in young and (sub)adult seals, but not in pups. Both male
and female seals were infected. In both seals in which SePV was
detected in the serum, the numbers of red blood cells present in
the blood sample was determined. Grey seal HG06-130 had a red
blood cell (RBC) count of 3.6661012 cells/liter and harbor seal
PV12-410 had a mean RBC value of 3.6961012/liter (ranged
from 3.03 to 4.2961012 cells/liter during stay at the SRRC),
which were both lower than normal (reference values for a normal
RBC count are for both seal species of this age 3.9–5.761012 cells/
liter). Despite a low RBC count, the hemoglobin level of grey seal
HG06-130 was 9.2 mmol/liter, which was within the reference
values (8.4–14.9 mmol/liter). The mean hemoglobin level of
harbor seal 12–410 was somewhat lower than normal (mean value
8.4 mmol/liter, ranged from 6.7 to 9.6 mmol/liter during stay at
the SRRC).
Since samples from 1988 and 2002 were collected from seals
that had died during PDV outbreaks, the death of at least four
seals was related to infection with PDV and the role of SePV could
not be evaluated. In one grey seal that died in 2002
(HG020628.02) and in which SePV DNA was detected, the cause
of death was non-infectious and no other significant abnormalities
were observed upon necropsy of this animal (Table 1). One
harbor seal that died in 2002 (PV020628.13) had an intestinal
volvulus and no significant abnormalities were reported that could
be related to a viral infection, although it was positive for phocine
herpesvirus-1 (PhHV-1). Besides this seal, PhHV-1 was detected in
three additional spleen samples (Table 1).
Discussion
SePV was discovered in 2012 in a young harbor seal with severe
chronic meningo-encephalitis [12]. In the present study, we
demonstrated that SePV was already circulating among both
harbor and grey seals of Northwestern Europe since 1988,
although SePV was detected only in a relatively small number of
samples.
The partial NS and the complete VP2 gene analyzed in the
present study corresponded with highly variable regions of the
parvovirus B19 genome [28]. However, sequences of SePV
variants analyzed in the present study showed only one amino
acid substitution, which was detected in the most recent variant in
2012. This amino acid substitution was present in the VP2 protein
(S540T), but since both serine and threonine are polar amino acids
it is unlikely that this would have led to substantial conformational
change of the VP2 protein. Of interest, there was also only
Figure 2. Maximum likelihood tree of the VP2 gene and partial
NS1 gene of SePV. Phylogenetic maximum-likelihood tree with 500
bootstrap replicates of the nucleotide sequence of the VP2 genes (A)
and partial NS genes (B) of SePV variants and various viruses of the
genus Erythroparvovirus. Only bootstrap values .70 are indicated.
Genbank accession numbers: SePV-HG06130: KM252691, SePV-
HG020628.02: KM252694, SePV-PV121216.01: KM252698, SePV-
PV880823.6: KM252692, SePV-PV880927.20: KM252693, SePV12410:
KF373759, SePV-PV020628.13: KM252695, SePV-PV020718.12:
KM252696, SePV-PV020719.08: KM252697, bovine parvovirus 3:
AF406967, chipmunk parvovirus: GQ200736, rhesus macaque parvovi-
rus: AF221122, simian parvovirus: U26342, pig-tailed macaque parvo-
virus: AF221123, human parvovirus B19-Au: M13178, human parvovirus
B19-LaLi: AY044266, human parvovirus B19-V9: AJ249437.
doi:10.1371/journal.pone.0112129.g002
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minimal sequence variation between SePV detected in grey seals
and harbor seals, similar to what was reported for parapox viruses
in two species of pinnipeds and herpesviruses among phocids
[29,30]. These findings suggest that the metapopulation of harbor
and grey seals act as a single reservoir for these viruses.
Estimation of nucleotide substitutions rates of parvoviruses has
been the focus of multiple studies [31–34]. However, the number
of studies in which evolutionary dynamics of parvoviruses were
evaluated over a period of more than 20 years is limited, especially
in a wildlife population [32,35,36]. In the present study, we
evaluated the annual nucleotide substitutions rates of SePV using
samples from 1988 to 2012, which is to our knowledge only the
second study performed for viruses of the genus Erythroparvovirus
over such a long period [35]. However, only a limited number of
samples was included in the present study and it could not be
excluded that the observed genetic variations were due to
polymorphisms of the NS and VP2 genes. In addition, only the
partial NS gene was sequenced and observed nucleotide substi-
tution rates might not be representative for the complete NS gene.
Of interest, the relatively low prevalence of this virus in
combination with the rapid population growth of both harbor and
grey seals from 1988 to 2012 [37] allowed to evaluate genetic
diversity of a parvovirus in a population without or with only low
herd immunity. Furthermore, harbor seals are generally known to
have a limited migration range [38], which minimizes the gene
flow of seals that might have differences in susceptibility to this
virus and limits the chance of recombination with other
parvoviruses from seals of other areas [39]. Although only a
relatively low number of different virus variants was studied,
observed annual nucleotide substitutions rates were similar to
those of other parvoviruses [31–34]. Despite this relatively high
mutation rate, only one amino acid substitution was detected in
the VP2 gene and none in the NS gene, suggesting that natural
selection suppressed amino acid changes for both genes. Of
interest, also no nucleotide changes were detected in the consensus
SePV sequence that was detected in two serum samples collected
from seal 12–410 with an interval of five weeks.
SePV was first discovered in a seal with meningo-encephalitis
[12], while in the present and previous study SePV was also
detected in at least two seals without neurological signs. Since in
most cases SePV DNA was detected in seals that were also infected
with PDV and/or PhHV-1, the spectrum of clinical signs
associated with SePV infection remained unclear. Of interest,
results of the present study and a previous study [12] suggested a
higher prevalence of SePV during the PDV epizootic in 2002.
This might be related to immunosuppression in the seal
population following infection with PDV, which predisposes for
other viral infections [40]. Anemia or associated signs of low red
blood cell counts is one of the manifestations associated with
Erythroparvovirus infection in humans and non-human primates
[6,8,9]. In the present and previous study [12], in total two positive
samples were identified for which hematology parameters were
available. Both seals had relatively low red blood cells counts.
However, about 6% of the seals admitted to SRRC have low red
blood cells counts upon admission and there are various causes of
anemia or low red blood cell counts in seals, such as malnutrition,
hemorrhage, chronic disease, and intoxication [41]. Additional
studies need to be performed to elucidate the exact impact of
SePV infection in both harbor and grey seals.
In summary, the present study showed that SePV has been
circulating among both harbor and grey seals from Dutch coastal
waters at least from 1988 onwards. Analysis of sequence data
suggested that SePV circulating in the Dutch coastal waters
showed mutation rates similar to other parvoviruses while this
resulted in only one amino acid change. Although the number of
virus variants that was analyzed was limited, these results indicate
that SePV circulating among seals of the Dutch coastal waters
undergoes gradual alteration similar to human parvovirus B19
[35] but with strong negative selection for amino acid changes.
These results provide additional insights into the genetic diversity
of parvoviruses.
Supporting Information
Figure S1 Prevalence of SePV. Spleen tissues of harbor and
grey seals were tested for the presence of SePV DNA. Indicated is
the percentage of samples of spleens of seals in which SePV DNA
was detected by real-time PCR for all samples of both harbor and
grey seals (A), or for specific years for which samples were available
from grey seals (B) or harbor seals (C). Numbers above the x-axis
represent the number of samples that was tested.
(TIF)
Table S1 Overview of seal serum and tissue samples
used in the present study.
(DOCX)
Acknowledgments
The authors wish to thank all people who helped with collecting samples
during the PDV outbreaks in 1988 and 2002 for their commitment. In
addition, the authors wish to thank the Natural Environment Research
Council’s Sea Mammal Research Unit (United Kingdom) for providing
seal sample PV880823.6.
Author Contributions
Conceived and designed the experiments: RB RH MdG ADMEO.
Performed the experiments: RB RH ARG GJSC MWGvdB MdG.
Analyzed the data: RB RHMdG. Contributed reagents/materials/analysis
tools: ARG GJSC MWGvdB TK. Wrote the paper: RB RH MdG TK
ADMEO.
References
1. Cotmore SF, Tattersall P (2007) Parvoviral Host Range and Cell Entry
Mechanisms. In: Karl Maramorosch AJS, Frederick AM, editors. Advances in
Virus Research: Academic Press. pp. 183–232.
2. International Committee on Taxonomy of Viruses (2013) Virus Taxonomy:
2013 Release. Available: http://www.ictvonline.org/virusTaxonomy.asp.
3. Cotmore SF, Agbandje-McKenna M, Chiorini JA, Mukha DV, Pintel DJ, et al.
(2014) The family Parvoviridae. Arch Virol 159: 1239–1247.
4. Broliden K, Tolfvenstam T, Norbeck O (2006) Clinical aspects of parvovirus
B19 infection. J Intern Med 260: 285–304.
5. Bonvicini F, Puccetti C, Salfi NC, Guerra B, Gallinella G, et al. (2011)
Gestational and fetal outcomes in B19 maternal infection: a problem of
diagnosis. J Clin Microbiol 49: 3514–3518.
6. Heegaard ED, Brown KE (2002) Human parvovirus B19. Clinical microbiology
reviews 15: 485–505.
7. Douvoyianni M, Litman N, Goldman DL (2009) Neurologic Manifestations
Associated with Parvovirus B19 Infection. Clin Infect Dis 48: 1713–1723.
8. Green SW, Malkovska I, O’Sullivan MG, Brown KE (2000) Rhesus and pig-
tailed macaque parvoviruses: identification of two new members of the
erythrovirus genus in monkeys. Virology 269: 105–112.
9. O’Sullivan MG, Anderson DC, Fikes JD, Bain FT, Carlson CS, et al. (1994)
Identification of a novel simian parvovirus in cynomolgus monkeys with severe
anemia. A paradigm of human B19 parvovirus infection. J Clin Invest 93: 1571–
1576.
10. Yoo BC, Lee DH, Park SM, Park JW, Kim CY, et al. (1999) A novel parvovirus
isolated from Manchurian chipmunks. Virology 253: 250–258.
11. Allander T, Emerson SU, Engle RE, Purcell RH, Bukh J (2001) A virus
discovery method incorporating DNase treatment and its application to the
identification of two bovine parvovirus species. Proc Natl Acad Sci U S A 98:
11609–11614.
Molecular Epidemiology of Seal Parvovirus
PLOS ONE | www.plosone.org 6 November 2014 | Volume 9 | Issue 11 | e112129
12. Bodewes R, Rubio Garcia A, Wiersma LC, Getu S, Beukers M, et al. (2013)
Novel B19-like parvovirus in the brain of a harbor seal. PLoS ONE 8: e79259.
13. Greer LL, Whaley J, Rowles TK (2001) Euthanasia. In: CRC Handbook of
Marine Mammal Medicine (Dierauf, L and Gulland, FMD eds), 2nd edition.
CRC Press. Chapter 32, pp. 729–737.
14. Rijks JM, Read FL, van de Bildt MW, van Bolhuis HG, Martina BE, et al.
(2008) Quantitative analysis of the 2002 phocine distemper epidemic in the
Netherlands. Vet Pathol 45: 516–530.
15. Rijks JM, Van de Bildt MW, Jensen T, Philippa JD, Osterhaus AD, et al. (2005)
Phocine distemper outbreak, The Netherlands, 2002. Emerg Infect Dis 11:
1945–1948.
16. Osterhaus AD, Vedder EJ (1988) Identification of virus causing recent seal
deaths. Nature 335: 20.
17. Osterhaus AD, Groen J, Spijkers HE, Broeders HW, UytdeHaag FG, et al.
(1990) Mass mortality in seals caused by a newly discovered morbillivirus. Vet
Microbiol 23: 343–350.
18. Jensen T, van de Bildt M, Dietz HH, Andersen TH, Hammer AS, et al. (2002)
Another phocine distemper outbreak in Europe. Science 297: 209.
19. Kerr JR (2000) Pathogenesis of human parvovirus B19 in rheumatic disease.
Ann Rheum Dis 59: 672–683.
20. Manning A, Willey SJ, Bell JE, Simmonds P (2007) Comparison of tissue
distribution, persistence, and molecular epidemiology of parvovirus B19 and
novel human parvoviruses PARV4 and human bocavirus. J Infect Dis 195:
1345–1352.
21. Katoh K, Standley DM (2013) MAFFT multiple sequence alignment software
version 7: improvements in performance and usability. Mol Biol Evol 30: 772–
780.
22. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S (2013) MEGA6:
Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol 30: 2725–
2729.
23. Posada D (2008) jModelTest: phylogenetic model averaging. Mol Biol Evol 25:
1253–1256.
24. Drummond AJ, Suchard MA, Xie D, Rambaut A (2012) Bayesian phylogenetics
with BEAUti and the BEAST 1.7. Mol Biol Evol 29: 1969–1973.
25. Minin VN, Bloomquist EW, Suchard MA (2008) Smooth skyride through a
rough skyline: Bayesian coalescent-based inference of population dynamics. Mol
Biol Evol 25: 1459–1471.
26. Kosakovsky Pond SL, Frost SD (2005) Not so different after all: a comparison of
methods for detecting amino acid sites under selection. Mol Biol Evol 22: 1208–
1222.
27. VanDevanter DR, Warrener P, Bennett L, Schultz ER, Coulter S, et al. (1996)
Detection and analysis of diverse herpesviral species by consensus primer PCR.
J Clin Microbiol 34: 1666–1671.
28. Norja P, Eis-Hubinger AM, Soderlund-Venermo M, Hedman K, Simmonds P
(2008) Rapid sequence change and geographical spread of human parvovirus
B19: comparison of B19 virus evolution in acute and persistent infections. J Virol
82: 6427–6433.
29. Martina BE, Jensen TH, van de Bildt MW, Harder TC, Osterhaus AD (2002)
Variations in the severity of phocid herpesvirus type 1 infections with age in grey
seals and harbour seals. The Veterinary Record 150: 572–575.
30. Nollens HH, Gulland FMD, Jacobson ER, Hernandez JA, Klein PA, et al.
(2006) Parapoxviruses of seals and sea lions make up a distinct subclade within
the genus Parapoxvirus. Virology 349: 316–324.
31. Shackelton LA, Holmes EC (2006) Phylogenetic evidence for the rapid evolution
of human B19 erythrovirus. J Virol 80: 3666–3669.
32. Shackelton LA, Parrish CR, Truyen U, Holmes EC (2005) High rate of viral
evolution associated with the emergence of carnivore parvovirus. Proc Natl Acad
Sci U S A 102: 379–384.
33. Parrish CR, Aquadro CF, Strassheim ML, Evermann JF, Sgro JY, et al. (1991)
Rapid antigenic-type replacement and DNA sequence evolution of canine
parvovirus. J Virol 65: 6544–6552.
34. Zehender G, De Maddalena C, Canuti M, Zappa A, Amendola A, et al. (2010)
Rapid molecular evolution of human bocavirus revealed by Bayesian coalescent
inference. Infect Genet Evol 10: 215–220.
35. Suzuki M, Yoto Y, Ishikawa A, Tsutsumi H (2009) Analysis of nucleotide
sequences of human parvovirus B19 genome reveals two different modes of
evolution, a gradual alteration and a sudden replacement: a retrospective study
in Sapporo, Japan, from 1980 to 2008. J Virol 83: 10975–10980.
36. Allison AB, Kohler DJ, Fox KA, Brown JD, Gerhold RW, et al. (2013) Frequent
cross-species transmission of parvoviruses among diverse carnivore hosts. J Virol
87: 2342–2347.
37. Trilateral Seal Expert Group (TSEG) (2013) Aerial surveys of Harbour Seals in
the Wadden Sea in 2013. Available: www.waddensea-secretariat.org/sites/
default/files/downloads/TMAP_downloads/Seals/aerial_surveys_of_harbour_
seals_in_the_wadden_sea_in_2013.pdf. Site accessed July 30, 2014.
38. Dietz R, Teilmann J, Andersen SM, Riget F, Olsen MT (2013) Movements and
site fidelity of harbour seals (Phoca vitulina) in Kattegat, Denmark, with
implications for the epidemiology of the phocine distemper virus. Ices J Mar Sci
70: 186–195.
39. Goodman SJ (1998) Patterns of extensive genetic differentiation and variation
among European harbor seals (Phoca vitulina vitulina) revealed using
microsatellite DNA polymorphisms. Mol Biol Evol 15: 104–118.
40. Rijks JM (2008) Phocine distemper revisited: Multidisciplinary analysis of the
2002 phocine distemper virus epidemic in the Netherlands [PhD. thesis]:
Erasmus University Rotterdam.
41. Bossart GD, Reidarson TH, Dierauf LA, Duffield DA (2001) Clinical pathology.
In: CRC Handbook of Marine Mammal Medicine (Dierauf, L and Gulland,
FMD eds) 2nd edition. CRC Press. Chapter 19, pp. 394.
Molecular Epidemiology of Seal Parvovirus
PLOS ONE | www.plosone.org 7 November 2014 | Volume 9 | Issue 11 | e112129
